Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 16.82 is in line with its 5-year average of 15.95, around the middle of its 5-year range (7.09–27.90).
As of the fiscal period ended Tuesday, June 30, 2026. 57.26% above its 12-month average of 10.70.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 16.82.
QUICK RATIO (ACID-TEST)
16.82
QUICK RATIO (ACID-TEST) AVG TTM
10.70
QUICK RATIO (ACID-TEST) AVG 3Y
13.84
QUICK RATIO (ACID-TEST) AVG 5Y
15.95
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
+57.26%
CURRENT VS 3Y AVG
+21.58%
CURRENT VS 5Y AVG
+5.46%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.35
median of 870 covered companies
CURRENT VS SECTOR MEDIAN
+401.39%
vs the sector median at left
Aura Biosciences, Inc.
Market Cap
$638.20M
Quick Ratio (Acid-Test)
16.82
TTM Avg
10.70
3Y Avg
13.84
5Y Avg
15.95
Market Cap
$634.30M
Quick Ratio (Acid-Test)
5.12
TTM Avg
4.05
3Y Avg
4.17
5Y Avg
7.50
Market Cap
$632.16M
Quick Ratio (Acid-Test)
3.05
TTM Avg
5.21
3Y Avg
6.01
5Y Avg
5.25
Market Cap
$656.59M
Quick Ratio (Acid-Test)
8.03
TTM Avg
12.16
3Y Avg
13.50
5Y Avg
14.42
Market Cap
$619.15M
Quick Ratio (Acid-Test)
2.55
TTM Avg
2.67
3Y Avg
4.11
5Y Avg
5.17
Market Cap
$657.89M
Quick Ratio (Acid-Test)
1.15
TTM Avg
1.35
3Y Avg
1.35
5Y Avg
1.35
Market Cap
$660.29M
Quick Ratio (Acid-Test)
5.53
TTM Avg
8.02
3Y Avg
10.47
5Y Avg
14.43
Market Cap
$611.57M
Quick Ratio (Acid-Test)
31.45
TTM Avg
23.29
3Y Avg
26.88
5Y Avg
23.21
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aura Biosciences, Inc. (AURA) | $638.20M | 16.82 | 10.70 | 13.84 | 15.95 |
| Zevra Therapeutics, Inc. (ZVRA)vs › | $634.30M | 5.12 | 4.05 | 4.17 | 7.50 |
| Prime Medicine, Inc. (PRME)vs › | $632.16M | 3.05 | 5.21 | 6.01 | 5.25 |
| OmniAb, Inc. (OABI)vs › | $630.63M | 4.80 | 4.27 | 4.36 | 3.29 |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $656.59M | 8.03 | 12.16 | 13.50 | 14.42 |
| SOPHiA GENETICS S.A. (SOPH)vs › | $619.15M | 2.55 | 2.67 | 4.11 | 5.17 |
| Starling Oncology, Inc. (STLN)vs › | $657.89M | 1.15 | 1.35 | 1.35 | 1.35 |
| Annexon, Inc. (ANNX)vs › | $660.29M | 5.53 | 8.02 | 10.47 | 14.43 |
| Climb Bio, Inc. (CLYM)vs › | $611.57M | 31.45 | 23.29 | 26.88 | 23.21 |
| Helus Pharma Inc. (HELP)vs › | $666.95M | 10.97 | 8.63 | 10.75 | 10.66 |
Quick Ratio
16.82
Excludes inventory
Current Ratio
16.82
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 16.82 |
| 2026-03-31 | 7.09 |
| 2025-12-31 | 8.15 |
| 2025-09-30 | 9.04 |
| 2025-06-30 | 12.39 |
| 2025-03-31 | 11.06 |
| 2024-12-31 | 10.77 |
| 2024-09-30 | 12.47 |
| 2024-06-30 | 18.54 |
| 2024-03-31 | 21.97 |
| 2023-12-31 | 18.76 |
| 2023-09-30 | 14.13 |
| 2023-06-30 | 18.69 |
| 2023-03-31 | 22.09 |
| 2022-12-31 | 18.81 |
| 2022-09-30 | 11.63 |
| 2022-06-30 | 21.97 |
| 2022-03-31 | 27.90 |
| 2021-12-31 | 20.90 |
| 2021-09-30 | 14.31 |
| 2021-06-30 | 17.47 |
| 2021-03-31 | 29.44 |
| 2020-12-31 | 6.94 |
| 2020-09-30 | 0.00 |
| 2020-06-30 | 0.00 |
| 2020-03-31 | 0.00 |
